Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.57 |
| ▸ | NTSR2 | O95665 | 12/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 12/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 12/20 | 0.54 |
| ▸ | REN | P00797 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455325 | 0.89 | EPHA2 (0.57) | EPHA2 | |
| SCHEMBL31257023 | 0.88 | EPHA2 (0.57) | EPHA2NTSR2NTSR1SORT1SLC6A2 | |
| SCHEMBL13807691 | 0.87 | EPHA2 (0.57) | EPHA2NTSR2NTSR1SORT1 | |
| SCHEMBL30775524 | 0.86 | F2 (0.56) | EPHA2SLC6A2 | |
| SCHEMBL31558390 | 0.86 | F2 (0.56) | EPHA2SLC6A2 | |
| SCHEMBL31307264 | 0.86 | NTSR2 (0.56) | EPHA2NTSR2NTSR1SORT1 | |
| SCHEMBL30974439 | 0.86 | EPHA2 (0.55) | EPHA2NTSR2NTSR1SORT1REN | |
| SCHEMBL9807245 | 0.85 | EPHA2 (0.61) | EPHA2NTSR2NTSR1SORT1REN | |
| SCHEMBL10592955 | 0.85 | NTSR2 (0.64) | NTSR2NTSR1SORT1 | |
| SCHEMBL29786697 | 0.85 | MAPK8 (0.58) | EPHA2NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | claimed |
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (OR) | 2024-10-17 | — | — | US | disclosed |
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343760-A1 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | ARGLU1, TPX2, RXFP1 | EPHA2 1164/4885NTSR2 124/4885NTSR1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.